Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Adv Ther (Weinh). 2021 Jan 20;4(3):2000243. doi: 10.1002/adtp.202000243

Figure 6: SQ3370 Local Drug Activation Technology triggers systemic anti-tumor immune response.

Figure 6:

Local Dox activation and exposure in injected tumor site activates APC cells such as iDCs (immature dendritic cells). Activated cells, now mDCs (mature dendritic cells), migrate to lymph nodes and present tumor associated antigen (TAA) to naïve t-cells. The interaction leads to expansion of tumor specific effector T-cells and down regulation of tumor specific regulatory T-cells. Effector T-cells then move to the periphery and generate a systemic anti-tumor immune response, leading to lymphocyte infiltration into both injected and non-injected tumors.